192 filings
6-K
AFMD
Affimed N.V.
28 Mar 24
Affimed Reports 2023 Financial Results and Operational Progress
4:05pm
20-F
2023 FY
AFMD
Affimed N.V.
Annual report (foreign)
28 Mar 24
11:37am
6-K
AFMD
Affimed N.V.
11 Mar 24
Current report (foreign)
4:05pm
6-K
AFMD
Affimed N.V.
6 Mar 24
Affimed Announces 1-for-10 Reverse Stock Split
6:34am
6-K
AFMD
Affimed N.V.
8 Jan 24
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
4:45pm
6-K
usrkc5oxaic43 4e8zn9
8 Jan 24
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8:11am
6-K
gm7ywwzyv it
11 Dec 23
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
6:10am
6-K
syvpvpc
30 Nov 23
Current report (foreign)
7:00am
6-K
qg75a
14 Nov 23
Unaudited consolidated interim statements of comprehensive loss
8:31am
6-K
1buwhm
4 Oct 23
Affimed Announces Listing Transfer to NASDAQ Capital Markets
6:40am
6-K
ooyfwa95f
10 Aug 23
Unaudited consolidated interim statements of comprehensive loss
6:45am
6-K
oehl1rio
22 Jun 23
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
6:41am
6-K
gpp3qvc mju0b
5 Jun 23
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort
6:04am
6-K
8c90x 64szp9xd
23 May 23
Unaudited consolidated statements of comprehensive loss
6:46am
6-K
t8a4 d816aybxf
22 May 23
Affimed Announces Annual General Meeting of Shareholders
6:49am
6-K
mr7suhrt ts2ngv
6 Apr 23
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding
5:07pm
S-8
1nqfw
23 Mar 23
Registration of securities for employees
4:53pm
424B5
qogkjexwl 2uf8u
23 Mar 23
Prospectus supplement for primary offering
4:50pm
6-K
pok k6m7a4guy261u5
23 Mar 23
Affimed Reports 2022 Financial Results and Operational Progress
4:13pm